Miromatrix Medical Inc.
Miromatrix Medical Inc. (MIRO): 11 pipeline candidates · ~7 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.6 months
D/E 0.51 · 0% dilution
Lead: Approved
11 candidates
N/A
N/A
A transparent, data-derived signal for Miromatrix Medical Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$6.9M
Quarterly Burn
$4.6M
Runway
6.6 mo
Revenue
$11K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| amoxicillin | Approved |
| bupropion | Approved |
| celecoxib | Approved |
| diclofenac | Approved |
| diphenhydramine | Approved |
| famotidine | Approved |
| mirokidney | Preclinical |
| miroliver | Phase 1 |
| miroliverelap | Phase 1 |
| propoxyphene napsylate | Approved |
Showing 10 of 11 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Miromatrix Medical Inc.'s pipeline?
Miromatrix Medical Inc. (MIRO) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Miromatrix Medical Inc.'s lead drug candidate?
Miromatrix Medical Inc.'s most advanced tracked candidate is amoxicillin (Approved) for 1 INDICATIONS AND USAGE Amoxicillin capsules are a penicillin-class antibacterial indicated for treatment of infections due to susceptible strains of designated microorganisms. Infections of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract. ( 1.1 to 1.4 ) In combination for treatment of H. pylori infection and duodenal ulcer disease. ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules and other antibacterial drugs, amoxicillin capsules should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Infections of the Ear, Nose, and Throat Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . 1.2 Infections of the Genitourinary Tract Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Escherichia coli, Proteus mirabilis , or Enterococcus faecalis . 1.3 Infections of the Skin and Skin Structure Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli . 1.4 Infections of the Lower Respiratory Tract Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae . 1.5 Helicobacter pylori Infection Triple therapy for Helicobacter pylori with clarithromycin and lansoprazole: Amoxicillin capsules, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pyl.
What is Miromatrix Medical Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Miromatrix Medical Inc. has approximately 6.6 months of cash runway.
Who is the CEO of Miromatrix Medical Inc.?
Flying Cloud Drive is the chief executive officer of Miromatrix Medical Inc. (MIRO).
Get the full picture on Miromatrix Medical Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.